Kinetics and persistence of anti‐SARS‐CoV‐2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort

Šošić, Lara; Paolucci, Marta; Duda, Agathe; Hasler, Fabio; Walton, Senta M.; Kündig, Thomas M.; Johansen, Pål

doi:10.1002/iid3.583

Cited by 6 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody presence increased in RD patients from weeks 1 to 9 after the second vaccination, demonstrating that RD patients need more time to seroconvert than in a recent study of healthy controls, where all seroconverted within 14 days of the first mRNA vaccination [ 41 ]. We need kinetic studies of antibody presence and levels in RD patients to avoid bias when comparing different studies of humoral responses to COVID-19, as the optimal timepoint for antibody measurement after vaccination in RD patients has not been established [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour

Ammitzbøll

Thomsen

Andersen

et al. 2022

Modern Rheumatology

View full text Add to dashboard Cite

Objectives We investigated the effect of a two-dose messenger ribonucleic acid (mRNA) vaccine on antibody levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and patient behaviour and shielding concerning fear of coronavirus disease 2019 (COVID-19) in patients with systemic lupus erythematosus or rheumatoid arthritis. Methods Three hundred and three patients and 44 blood donors were included. All patients received two doses of an mRNA vaccine and had total antibodies against SARS-CoV-2 measured before vaccination and 2 and 9 weeks after the second vaccination. Further, patients answered an electronic questionnaire before and after vaccination concerning behaviour, anxiety, and symptoms of depression (Patient Health Questionnaire-9). Results Significantly fewer patients (90%) had measurable antibodies against SARS-CoV-2 compared to blood donors (100%) after the second vaccination (P < .001). Treatment with rituximab was the strongest predictor of an unfavourable vaccine response, as only 27% had measurable antibodies. Nearly all patients (97%) not treated with rituximab experienced seroconversion. Prednisone and methotrexate had a negative effect on seroconversion, but no effect of age or comorbidity was observed. Patients experienced significant improvement after vaccination in 10 out of 12 questions regarding behaviour and fear of COVID-19, while no change in Patient Health Questionnaire-9 or anxiety was observed. Conclusion We find a very high seroconversion rate among rheumatic patients and reduced self-imposed isolation and shielding after COVID-19 vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour

Ammitzbøll

Thomsen

Andersen

et al. 2022

Modern Rheumatology

View full text Add to dashboard Cite

show abstract

“…Whether the vaccines have the ability to trigger mucosal immune response, or whether the vaccine against COVID-19 triggered a robust humoral immunity is mostly unexpectable (Barda et al, 2021). In the scope of vaccination worldwide, the applicability of a highly robust antibody assay, to be considered a cost effective less invasive method was a target goal to be achieved to track community health immunity and measure the extent of success of vaccination strategy globally (Šošić et al, 2021, Cristiano et al, 2021, Makhoul et al, 2020. Based on the discussion, a reliable quantitative and neutralizing assay against SARS-COV-2 are crucial to follow up immune response to the vaccine, and such tests appears mandatory, if we can establish a link between the antibody titers and future shielding against reinfection was made possible (Ech-chaouy et al, 2021;Infantino et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Comparative ELISA Detection of SARS-COV-2 Monoclonal Antibodies in Patients` Serum, Saliva, and Nasal Fluid in Iraq

Mohammed¹,

Abdul-Rahman²

2023

IUJAS

View full text Add to dashboard Cite

Precise management of COVID-19 infection and global pandemic requires a precise assay of SARS-COV-2 antibodies. Spike protein and RBD specific serum monoclonal antibodies has been known to be elicited with the currently approved mRNA vaccine for COVID-19. Since combating SARS-CoV-2 infection begins as early at the viral entry port, mediated by mucosal immunity; whether the currently approved vaccines have the capacity to elicit mucosal immunity is still to be studied. Method; We conducted our research to detect SARS-Cov-2 IgA-RBD and IgG-NCP, in a set of a randomized three patients’ groups (total 55 subjects, randomized into 20 (Non previously infected control, 20 fully vaccinated people from AlSalam teaching hospital vaccination ward upon receiving the vaccine doses, and 15 patients newly recovered from SARS-CoV-2 infection from AlShifaa quarantine hospital after remission from COVID-19 infection and preparing to discharge) in three fluid samples serum, saliva and nasal fluid, for a total of three samples per participant, to make a total of 165 samples to be tested, using a commercial immunoassay kit (Anti-SARS-CoV-2 ELISA RBD IgA, and Anti-SARS- CoV-2 NCP ELISA IgG) the study was designed to assess the immunoglobulins levels in each sample from different health status and anatomical locations to give the statistical difference and the correct conclusion regarding this study. Statistical analysis was performed using SPSS version 24, as well as Microsoft excel version (16.0.15028), test equations were performed via Mann-Whitney U Test, as well as The Kruskal-Wallis H test, to evaluate the non-gaussian distribution among the study group, for each of the outcomes, p < 0.05 was undertaken as statistically significant. Results; Our work showed that two doses of mRNA BNT162b2 vaccine Comirnaty (Pfizer/BioNTech, New York, NY, USA), elicited a robust anti SARS-CoV-2 nasal and salivary IgA and IgG monoclonal antibody protection (as compared to control 0.625 COI, the vaccinated subjects resulted in a higher median salivary concentration of IgG NCP values as 1.69 COI, with a p-value of 0.0001. same goes for median salivary concentration of IgA RBD with value of 2.875 ± 1.276, as compared to control median values of 0.667 ± 0.208), (as compared to control 0.462 ± 0.2369, the vaccinated subjects resulted in a higher median nasal concentration of IgG NCP values as 1.944 ± 0.694, with a p-value of 0.0001. Same goes for median nasal concentration of IgA RBD with value of 1.941 ± 0.53, as compared to control median values of 0.681 ± 0.226). Two injections 25 days a part shown to trigger a stronger titer of protective immunity as compared to single early shot, still it`s less robust compared to the titers measured for the recovered subjects from COVID-19 infection. Taking into consideration that there was a lack of trustable ELISA based assays with specially designed kit for this purpose, focusing on nasal and salivary secretions, the current study that our pre investigational and investigational data are consistent. The results of this study indicates that a protective antigen specific nasal and salivary monoclonal antibody, can be triggered following proper vaccination regimen with mRNA COVID-19 vaccine, so this paves the way for using mucosal protective antibodies detection kits, as a suitable alternative option as a less invasive method compared to serum investigations, for detecting the protection against SARS-Cov-2 infection, induced by vaccine. The vaccinated subjects are significantly better tested via IgA in Saliva as compared to IgG, because of the higher median values for the IgA vs IgG, 2.875 ± 1.276 and 2.083 ± 1.610 respectively with a p-value of 0.008. in a similar state the IgA is the best test for the convalescent subjects in term of nasal fluid samples investigations, as the median value are comparatively higher than median value of IgG, 2.024 ± 0.520 and 1.786 ± 1.115 respectively.

show abstract

Kinetics and persistence of anti‐SARS‐CoV‐2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort

Šošić

Paolucci

Duda

et al. 2021

Immunity Inflam & Disease

Self Cite

View full text Add to dashboard Cite

Introduction: Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), substantial effort has been made to gain knowledge about the immunity elicited by infection or vaccination. Methods: We studied the kinetics of antibodies and virus neutralisation induced by vaccination with BNT162b2 in a Swiss cohort of SARS-CoV-2 naïve (n = 40) and convalescent (n = 9) persons. Blood sera were analysed in a live virus neutralisation assay and specific IgG and IgA levels were measured by enzyme-linked immunoassay and analysed by descriptive statistics. Results: Virus neutralisation was detected in all individuals 2-4 weeks after the second vaccine. Both neutralisation and antibodies remained positive for >4 months. Neutralisation and antibodies showed positive correlation, but immunoglobulin G (IgG) and immunoglobulin A (IgA) seroconversion took place 2-4 weeks faster than neutralisation. Spike-protein specific IgG levels rose significantly faster and were more stable over time than virus neutralisation titres or IgA responses. For naïve but not convalescent persons, a clear boosting effect was observed. Convalescent individuals showed faster, more robust and longer-lasting immune responses after vaccination compared to noninfected persons. No threshold could be determined for spike proteinspecific IgG or IgA that would confer protection in the neutralisation assay, implicating the need for a better correlate of protection then antibody titres alone.Conclusions: This study clearly shows the complex translation of antibody data and virus neutralisation, while supporting the evidence of a single

show abstract

Kinetics and persistence of anti‐SARS‐CoV‐2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort

Cited by 6 publications

References 43 publications

COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour

COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour

Comparative ELISA Detection of SARS-COV-2 Monoclonal Antibodies in Patients` Serum, Saliva, and Nasal Fluid in Iraq

Kinetics and persistence of anti‐SARS‐CoV‐2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort

Contact Info

Product

Resources

About